Lyell Immunopharma, Inc. (LYEL) company profile
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
About Lyell Immunopharma
Pharmaceutical Preparations, SIC 2834
Lyell is a clinical-stage biotechnology company that develops autologous chimeric antigen receptor T-cell therapies for cancer patients. The company focuses on hematologic malignancies and solid tumors, modifying patient immune cells to target cancerous tissues. Its lead product candidate is rondecabtagene autoleucel, a dual-targeting CD19 and CD20 cell therapy in clinical trials for large B-cell lymphoma. The company also develops LYL273, a cell therapy candidate targeting guanylyl cyclase C for patients with advanced metastatic colorectal cancer. Lyell's therapies target cancer patients with relapsed, refractory, or advanced malignancies.
The company conducts clinical trials across the United States, Canada, and Australia, with one pivotal trial enrolling patients at about twenty-five sites. Lyell operates a dedicated manufacturing facility called the LyFE Manufacturing Center to produce cell therapies for clinical trials. In addition, its global licensing rights for LYL273 cover worldwide territories excluding mainland China, Hong Kong, Macau, and Taiwan. The provided text does not state the location of the company's headquarters.
Summary of the business section of Lyell Immunopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lyell Immunopharma, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 201 Haskins Way 94080
- Phone
- (650) 695-0677
- Website
- lyell.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- LYEL
- Exchange
- Nasdaq
- IPO date
- Jun 21, 2021
- Shares outstanding
- 25M, Aug 3, 2026
- Public float
- $129.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Jun 2, 2025
- SEC CIK
- 1806952
- CUSIP
- 55083R203
- ISIN
- US55083R2031
- FIGI
- BBG00RNXFN14
- Share class FIGI
- BBG00RNXFN23
- EIN
- 83-3006753
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lynn Seely | President and CEO, Director | 63,354 |
| Gary K. Lee | Chief Scientific Officer | 16,091 |
| Veronica Sanchez Bulis | VP, Corporate Controller | 14,383 |
| Stephen J. Hill | Chief Operating Officer | 16,728 |
| Jarrad Mattieu Aguirre | Chief Medical Officer | 19,857 |
| David Shook | Chief Medical Officer | 20,423 |
| Smital Shah | Chief Fin. and Bus. Officer | – |
| Mark A. Meltz | General Counsel | – |
| Charles W. Newton | Chief Financial Officer | 25,306 |
| Matthew Lang | Chief Business Officer | 162,500 |
| Richard Klausner | Director | 190,557 |
| Sumant Ramachandra | Director | 10,000 |
| Elizabeth G. Nabel | Director | – |
| Otis W. Brawley | Director | 1,782 |
| William Jl Rieflin | Director | – |
| Mark Bachleda | Director | – |
| Cathy Friedman | Director | 16,818 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.22M | $9.64M | $2.01M | $44 | – |
| FY2024 Elizabeth Homans | $0 | $0 | $1.61M | $18 | – |
| FY2024 Lynn Seely MD | $1.50M | -$3.24M | $1.61M | $18 | – |
| FY2023 Elizabeth Homans | $0 | $0 | $3.21M | $56 | – |
| FY2023 Lynn Seely MD | $2.65M | -$7.94M | $3.21M | $56 | – |
| FY2022 | $12.12M | -$7.44M | $4.00M | $45 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Lynn Seely, M.D. President, Chief Executive Officer and Director | $690.17K | $186.81K | $2.91M | $414.00K | $23.74K | $4.22M | +182% |
| Stephen Hill Chief Operating Officer | $529.47K | $62.27K | $1.18M | $291.50K | $9.59K | $2.08M | +55% |
| Gary Lee, Ph.D. Chief Scientific Officer | $520.02K | $62.27K | $1.09M | $260.00K | $6.79K | $1.94M | +48% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 21, 2021
- Offer price
- $17.00
- Securities offered
- 25,000,000
- Gross proceeds
- $425.00M
- Exchange
- Nasdaq
- First trading day
- Jun 18, 2021
- First-day close
- $16.20-4.7%
- Lock-up ends (est.)
- Dec 15, 2021
“The initial public offering price of our common stock is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 24, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 31, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 21, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 14, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?